Pay in 4 interest-free payments of $5.05 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Understanding how the medications work, what clinical studies found, and how their side effects compare can help patients make choices aligned with their health history, goals, and medical supervision
The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program
sin embargo, con EMPA hubo una reduccin significativa del 38% del riesgo relativo de muerte por causa CV, una reduccin significativa del 32% en todas las causas de mortalidad, y una reduccin significativa del 35% de hospitalizacin por IC, convirtindose en el primer estudio publicado con nuevos frmacos que demostr un impacto CV favorable en pacientes de alto riesgo vascular
Oral GLP-1 approvals and expanded manufacturer programs are likely to shift some demand away from injectables, enhance adherence for patients preferring pills, and introduce new pricing tiers that reflect different distribution models
